

**CURRICULUM VITAE**  
**PETER SOCRATES CRETICOS, M.D.**

---

Peter S. Creticos, M.D.

**I Current Appointment:**

Associate Professor of Medicine  
Department of Medicine  
Division of Allergy and Clinical Immunology  
The Johns Hopkins University School of Medicine

Active Staff  
Johns Hopkins Hospital  
Baltimore, MD 21205

**II Personal Data:**

Business Address: The Johns Hopkins University School of Medicine  
Division of Clinical Immunology  
The Johns Hopkins Asthma and Allergy Center  
5501 Hopkins Bayview Circle - Room 2B.57  
Baltimore, Maryland 21224-6801

Date of Birth: February 16, 1949  
Telephone: (410) 550-2112  
Fax: (410) 550-3666  
E-mail: pcretic@jhmi.edu

**III Education and Training:**

Undergraduate:	1967-1971	University of North Carolina Chapel Hill, North Carolina B.A. Degree; Chemistry
Graduate:	1974-1978	The Medical University of South Carolina Charleston, South Carolina M.D. Degree
Postdoctoral:	1978-1979	Internship - Internal Medicine Department of Medicine The Medical University of South Carolina Charleston, South Carolina
	1979-1981	Residency - Internal Medicine Department of Medicine The Medical University of South Carolina Charleston, South Carolina
	1981-1983	Fellowship - Department of Medicine Division of Allergy and Clinical Immunology The Johns Hopkins University School of Medicine Baltimore, Maryland

**IV Certification:**

Medical License No. 9307, State of South Carolina  
 National Board of Medical Examiners  
 Diplomate (Cert. No. 198810)

Medical License No. D29641, State of Maryland

**V Professional Experience:**

1971-1972	Research Chemist Hardwicke Chemical Company Elgin, South Carolina
1972-1974	Research Chemist Westvaco Corporation Organic Chemistry Division Charleston, South Carolina
1983-1984	Instructor - Department of Medicine Division of Allergy and Clinical Immunology The Johns Hopkins University School of Medicine Baltimore, Maryland
1984-1991	Assistant Professor - Department of Medicine Division of Allergy and Clinical Immunology The Johns Hopkins University School of Medicine Baltimore, Maryland
1991-present	Associate Professor - Department of Medicine Division of Allergy and Clinical Immunology The Johns Hopkins University School of Medicine Baltimore, Maryland

**VI Institutional Administrative Appointments:**

1983 - present	Johns Hopkins Hospital, Baltimore, MD 21205 Active Staff
1986 - present	Associate Director Provocation Laboratories/Allergy Section
1986 - 1989	Associate Director Johns Hopkins Centers for Asthma and Allergic Diseases
1989 - 1990	Co-Director; Patient Clinical Care Units Johns Hopkins Asthma and Allergy Center
1990 - present	Medical Director; Asthma and Allergic Diseases Johns Hopkins Asthma and Allergy Center
1996 - present	Clinical Director Division of Allergy and Clinical Immunology Johns Hopkins University School of Medicine

## VII Professional Activities:

### Society Memberships

1982-present	American Academy of Allergy, Asthma, and Immunology [Fellow]
1983-present	American College of Allergy, Asthma and Immunology [Member]
1985-present	Asthma and Allergy Foundation of America-Maryland Chapter
1990-present	Maryland Asthma and Allergy Society
1993-present	Southeastern Allergy Society

### Society Offices/Activities

American Academy of Allergy, Asthma and Immunology  
 Interest Section - Asthma, Rhinitis, and Related Respiratory Diseases  
 Chairman: 1997-1999  
 Vice Chairman: 1995-1997  
 Secretary: 1993-1995

#### Committees:

- a) Immunotherapy of Asthma: 1990-present  
 Chairman: 1993-1997
- b) Scientific Exhibits and Workshops: 1993-1995
- c) Allied Health: 1991-1995
- d) Bronchoprovocation: 1990-present
- e) Postgraduate Education: 1987-present  
 Chairman: 1988-1990

American College of Allergy, Asthma and Immunology  
 Committees:

- a) Workshops: 1991-1994
- b) Postgraduate Education: 1996-1998

Asthma and Allergy Foundation of America - Maryland Chapter  
 Medical Advisory Board: 1987-1995

### Extramural Professional Activities:

- a) Course Director [1988 - present]  
 Frontiers in Research and Clinical Management of Asthma & Allergy Symposium  
 Yearly 3-day didactic course for allergists, pulmonologists, otolaryngologists,  
 internists and primary care physicians who are actively engaged in clinical management  
 and in research of asthma and allergic diseases
- b) Report of the National Institute of Allergy and Infectious Diseases Task Force on  
 Immunotherapy and Allergy USDHHS September 1990 NIH Pub. No. 91-2414 Contributor,  
 Allergic Disease Section
- c) Clinical Research Coordinator's Course at the AAAAI  
 Research Course Co-director  
 Course Development Committee
- d) Fellows-in-Training Program of the Annual American Academy of Allergy and Immunology  
 Meeting (AAAAI)  
 Course Director  
 1992 Allergen Immunotherapy Course  
 1993 Indoor Allergens

1994 Immediate Hypersensitivity Testing for Aeroallergens  
Practicing Allergy in the Office Setting

- e) Immunotherapy Course – Session Chair/Course Director at the AAAAI  
1997 53rd Annual Meeting [San Francisco, California]  
1998 54th Annual Meeting [Washington, D.C.]
- f) Geneva, Switzerland – January 27 – 29, 1997  
Development of Position Paper to define international guidelines on allergen Immunotherapy  
[WHO Position Paper: “Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases”]
- g) Asthma Consultant's Course - Session Chair at the AAAAI  
1999 55th Annual Meeting [Orlando, Florida]: Controversies in the Use of Inhaled Steroids  
in Asthma and Rhinitis
- h) Minisymposium - Session Chair at the AAAAI  
1998 54<sup>th</sup> Annual Meeting [Washington, D.C.]: Immunotherapy  
1999 55<sup>th</sup> Annual Meeting [Orlando, Florida]: Immunotherapy  
2000 56<sup>th</sup> Annual Meeting [San Diego, California]: Immunotherapy  
2001 57<sup>th</sup> Annual Meeting [New Orleans, Louisiana]: Immunotherapy  
2002 58<sup>th</sup> Annual Meeting [New York, New York]: Immunotherapy  
2003 59<sup>th</sup> Annual Meeting [Denver, Colorado]: Immunotherapy

### Major Academic Committee Activities (Past 5 years)

1993 - present	Structure of Clinical Care Retreat Sub Group Co-Leader: with Dr. Jack Stobo, Chairman, Dept. of Medicine
1993 - 1994	Structure of Clinical Care Steering Committee Leader: Dr. Jack Stobo
1994 - 1995	Performance Based Components Committee Group Leader: Dr. David Hellmann, Acting Director, Dept. of Medicine
1994 - 1996	Faculty Clinical Practice Council Leader: Dr. Fred Wigley
1997- 1998	Clinical Research Task Force
1997 - present	Clinical Research Council
1997 - present	Divisional Directors and Clinical Chiefs Monthly Committee Meeting

### Consultantships

- Astra Pharmaceuticals  
Scientific Advisory Board [1995 – 2000]  
To provide advice and input regarding clinical research projects and marketing issues.
- Aradigm Corporation  
Scientific Advisory Board [1997 – present]  
To provide advice regarding areas of application of their innovative technology for drug  
delivery to the lungs.

- Dynavax Technologies [1998 – present]  
Consultant  
To provide advice and expertise with regard to therapeutic applications and the company's novel therapeutic vaccines in the field of allergic respiratory disease and/or related areas.
- Stallergenes [1996 – 1999]  
Consultant  
To inform and advise company with regard to therapeutic considerations and marketing issues in the field of allergy.
- ALK Abello [2000 – present]  
Consultant  
To provide advice regarding therapeutic methodologies and current marketing trends in the field of immunology.
- Aventis Pharmaceuticals [2002 – present]  
Consultant/Member of Scientific Advisory Board  
To review U.S. and European clinical trial data and provide input for design and protocol development of the company's novel therapeutic compounds (cytokine antagonists/immunomodulatory compounds/second-generation inhaled corticosteroids/third-generation antihistamines).
- GlaxoSmithKline [2002 – present]  
Member of International Scientific Advisory Board  
To review clinical trial decisions/protocol development/marketing issues related to the company's asthma and rhinitis product line.

## VIII Editorial

- |                |  |
|----------------|--|
| 1992 - present | Ad hoc referee for Journal of Allergy and Clinical Immunology, American Journal of Rhinology and New England Journal of Medicine |
| 1993 - present | Editorial Board, Clinical and Experimental Allergy   |

## IX Awards, Honors and Named or Honorary Lectures:

### Honors and Awards:

- |        |   |
|--------|---|
| 1978   | Medical University of South Carolina<br>Post graduate Research Competition<br>2nd place - (T mycoplasma work)   |
| 1983   | American College of Allergy<br>Travel Grant Recipient   |
| 1992 – | Best Doctors in America, Woodward/White, Inc. 1st Edition, [1992-1993]<br>General Allergy & Immunology [Area: Pharmacotherapy, Immunotherapy of Allergic Rhinitis/Asthma] [1992, 1994, 1996, 1998, 2000]. |
| 1994   | U.S. Olympic Committee Advisory Panel on Asthma   |
| 1995   | Appointed to EAACI Hellenic Organizing Committee<br>EAACI '97 Annual Meeting [Rhodes]   |

- 1998 Philip S. Norman Commemorative Lectureship  
1998 Norman Lecturer at the AAAAI Annual Meeting
- 1998 Asthma and Allergy Foundation of America - Maryland Chapter  
Physician of the Year
- 1998 Induction into the Collegium of Internationale Allergologicum

### **Named or Honorary Lectures [Last 5 years only]:**

#### **1999**

- Keystone Symposia on Molecular & Cellular Biology  
Incline Village, Nevada - January 14, 1999
  - a) Plenary Session: "Immunomodulation of Allergy/Asthma through Immune Tolerance"
- Oregon Allergy Society  
Portland, Oregon - February 12, 1999
  - a) "Therapeutic Vaccines for Allergic Disease"
- Northern California Allergy Society Annual Symposium  
San Francisco, California - February 13, 1999
  - a) "Novel Approaches to Immunotherapy: DNA Vaccines/Peptides/Anti-IgE"
- American Academy of Allergy Asthma & Immunology 55th Annual Meeting  
Orlando, Florida - February 27 - March 3, 1999
  - a) Immunotherapy Course: "New Methods of Immunotherapy in Allergic Rhinitis and Asthma: Naked DNA, Adjuvants, Oligonucleotides"
  - b) "Evaluation of Inhaled Corticosteroids"
  - c) Luncheon: "Immunotherapy for Asthma and Rhinitis"
  - d) Luncheon: "When and How to Use Standardized Extracts"
  - e) Asthma Consultant's Course: "Controversies in the Use of Inhaled Steroids"
- Greater Washington Asthma, Allergy, and Immunology Society  
Washington, D.C. – March 7, 1999
  - a) "The Concept of Gene Vaccination"
- New England Society of Allergy Annual Spring Meeting  
Westboro, Massachusetts – April 9, 1999
  - a) "Novel Approaches to Immunotherapy and Allergic Diseases and Asthma"
- The Rheingau Conference  
Mainz, Germany – August 26-28, 1999
  - a) "Provocation Models to Study Anti-Inflammatory Drugs"
  - b) "New Approaches to Immunomodulate the Immune System"
- Southeastern Allergy, Asthma, and Immunology Society 54<sup>th</sup> Annual Meeting  
Asheville, North Carolina – October 8-9, 1999
  - a) Plenary Session: "Gene Vaccinations"
- Society Espanol de Alergia e Inmunologia Clinica [Annual Congress]  
Le Coruna, Spain – October 10-12, 1999
  - a) Keynote Address: "Therapeutic Vaccines for Allergic Disease: DNA Vaccination/Adjuvants/Oligonucleotides"
  - b) Symposium: "Immunotherapy in Asthma"

- Southern Medical Association Annual Meeting  
Dallas, Texas – November 13, 1999
  - a) “Allergy Immunotherapy: Therapeutic Vaccines for Allergic Diseases”
  - b) “New and Future Developments in the Treatment of Allergic Diseases”

## 2000

- University of Pittsburgh Medical Center  
Pittsburgh, Pennsylvania – February 7, 2000
  - a) Allergy Department Seminar: “Novel Approaches to Immunotherapy”
  - b) Pulmonary Grand Rounds: “DNA Vaccination”
- American Academy of Allergy, Asthma, and Immunology 56<sup>th</sup> Annual Meeting  
San Diego, California – March 4-8, 2000
  - a) Immunotherapy Symposium: “New Approaches to Immunotherapy in Allergic Respiratory Disease: DNA Vaccination/Oligonucleotides/Adjuvants”
  - b) Leukotriene Symposium: “Considerations for Adjunctive Therapy in Moderate Asthma-Long Acting Beta<sub>2</sub>-agonists vs Leukotriene Modifiers”
- Utah Society of Allergy and Asthma  
Salt Lake City, Utah – March 17, 2000
  - a) “New Approaches to Immunomodulation: DNA/Peptides/Anti IgE”
- Frontiers in Research and Clinical Management of Asthma and Allergy  
Baltimore, Maryland – March 31-April 2, 2000
  - a) “DNA Vaccination in Allergic Disease”
  - b) “Anti-Inflammatory Treatment of Rhinitis: Corticosteroids vs Antihistamines”
  - c) “Strategies for Optimal Asthma Management”
- Carolina’s Medical Center Internal Medicine Grand Rounds  
Charlotte, North Carolina – April 25, 2000  
“Contemporary Management of Allergic Rhinitis”
- XVII Congreso Nacional de Alergia e Inmunologia  
Cordoba, Argentina – May 25-27, 2000
  - a) Keynote Address: “New Approaches to Immunotherapy: Gene Therapy/DNA Vaccination/Anti IgE”
  - b) Symposium: “Combination Treatment in Asthma”
- Pittsburgh Allergy Society  
Pittsburgh, Pennsylvania – June 6, 2000
  - a) “Inflammation in Asthma”
- Virginia Asthma and Allergy Society of Virginia Annual Meeting  
Virginia Beach, Virginia – June 17-18, 2000
  - a) Alexander McCausland Lecture Keynote Address: “The New Immunotherapy for Allergy”
  - b) Breakfast Seminar: “Judicious Use of Topical Nasal Steroids”
- Virginia American Academy of Pediatrics/Virginia Pediatric Society Annual Meeting  
Arlington, Virginia – September 24, 2000
  - a) “Therapeutic Options in Asthma Management”
- XVII International Congress of Allergology and Clinical Immunology [ICACI]  
Sydney, Australia – October 16-20, 2000
  - a) Plenary session: “New Approaches to Vaccine Development for Allergic Disease: DNA Vaccination/Oligonucleotides/Peptides”
  - b) Symposium: “Clinical Use of Third Generation Antihistamines”
  - c) Symposium: “New Considerations with Oral Immunotherapy”

- American College of Allergy, Asthma and Immunology Annual Meeting  
Seattle, Washington – November 3, 2000
  - a) Symposium: “The Role of IgE in the Pathology of Allergic Disease”
- Southampton University Chilworth Symposium  
Southampton, England – November 8 – 9, 2000  
“Clinical Considerations of Leukotriene Modifiers in the Treatment of Rhinitis”
- Southampton University Grand Rounds  
Southampton, England – November 10, 2000
  - a) “DNA Vaccination: Effect on Inducing T-cell Tolerance”

## 2001

- Western Society of Allergy, Asthma, and Immunology  
Lanai, Hawaii – January 22-25, 2001
  - a) “New Therapeutic Approaches to Immunization for Allergic Diseases – DNA Vaccination, Oligonucleotides, Adjuvants”
  - b) “Allergic Rhinitis – Comparative Effectiveness of and Immunologic Changes Associated with Oral and Intranasal Antihistamines and Steroids”
- American Academy of Allergy, Asthma, and Immunology  
New Orleans, Louisiana – March 17-21, 2001
  - a) Symposium: “Immunostimulatory Sequences”
  - b) Luncheon Seminar: “When and How to Use Standardized Extract”
  - c) Didactic Workshop: “Standardized Allergens in Clinical Practice”
- 16<sup>th</sup> Annual Frontiers in Research and Clinical Management of Asthma and Allergy Symposium  
Baltimore, Maryland – March 30-April 1, 2001
  - a) “Update on Leukotriene Receptor Antagonists in Rhinitis”
  - b) “Rationale for Combination Therapy for Asthma”
  - d) “DNA Vaccination: Oligonucleotide Constructs”
- Allergy, Asthma, and Immunology Society of Ontario’s Allergy Update 2001  
Toronto, Ontario, Canada – April 21, 2001
  - a) “Mechanisms of Allergic Reactions and Immunotherapy”
  - b) “New Methods of Immunotherapy, DNA Vaccination”
- Texas Allergy, Asthma, and Immunology Society 2001 Annual Meeting  
Houston, Texas – May 4, 2001
  - a) “New Therapeutic Vaccines for Allergic Disease: DNA/Oligonucleotides/Peptides”
- Texas Medical Association 2001 Annual Meeting  
Houston, Texas – May 5, 2001
  - a) “Optimal Prevention and Control of Asthma”
- Florida Allergy, Asthma, and Immunology Society 2001 Annual Meeting  
St. Augustine, Florida – June 8-10, 2001
  - a) “Combination Therapy for Asthma”
  - b) “New Directions in Allergen Immunotherapy”
- Brown University/Rhode Island Hospital Pfizer Visiting Professor  
Providence, Rhode Island – June 11-12, 2001
  - a) “Pulmonary Research Conference: New Methods of Immunization and Allergic Rhinitis/Asthma”
  - b) “Brown Internal Medicine Grand Rounds: Molecular Approaches to Airway Inflammation”
  - c) “Rhode Island Hospital Grand Rounds: Gene Therapy/DNA Vaccination/Adjuvants”

- d) “Meet the Professor: Case Studies in Asthma Management”
- Tulane/LSU Allergy and Immunology Division Conference Series  
New Orleans, Louisiana – August 15-16, 2001
    - a) “Allergy/Immunology Grand Rounds: Immunotherapy: Past, Present, and Future”
    - b) “Fellowship Training Program: Practical Aspects of Immunotherapy”
  - UNC Department of Pulmonary Medicine Clinical Conference  
Chapel Hill, North Carolina – October 4, 2001
    - a) “Asthma Management Decisions: Primary Intervention and Adjunctive Therapy”
  - Duke University Department of Pediatric Allergy/Immunology Research Conference  
Durham, North Carolina – October 5, 2001
    - a) “New Methods of Immunomodulation: Anti IgE/Peptide Immunotherapy/DNA Vaccines”
  - Maryland Academy of Family Practice 2001 Annual Meeting  
Solomons Island, Maryland – November 4, 2001
    - a) “Therapeutic Decisions in Asthma Management”

## 2002

- Massachusetts General Hospital/Brigham and Women’s Hospital Pulmonary Allergy Grand Rounds  
Boston, Massachusetts – January 30, 2002
  - a) Ether Dome Special Lecture: “New Methods of Immunotherapy in Allergic Respiratory Diseases: DNA Vaccination/Oligonucleotide Constructs/Peptide Immunization/Anti-IgE”
- Boston City-Wide Allergy Rounds  
Boston, Massachusetts – January 31, 2002
  - a) “New Methods of Immunotherapy in Allergic Respiratory Diseases: DNA”
  - b) “Vaccination/Oligonucleotide Constructs/Peptide Immunization/Anti-IgE”
- Massachusetts General Hospital Medical Grand Rounds  
Boston, Massachusetts – January 31, 2002
  - a) “Therapeutic Strategies in the Management of Asthma: Clinical Endpoints vs Inflammation”
- Vanderbilt Allergy/Immunology/Sinus/Asthma [Divisional Clinical Seminar]  
Nashville, Tennessee – February 20, 2002
  - a) “Diagnosis and Pharmacologic Approaches to Treatment of Allergic Rhinitis”
- American Academy of Allergy, Asthma, and Immunology  
New York, New York – March 1-7, 2002
  - a) Symposium: “Optimal Dosing of Immunotherapy”
  - b) Luncheon Seminar: “New Vaccine Approaches to Treating Allergic Disease”
- Utah Allergy Society  
Salt Lake City, Utah – March 19, 2002
  - a) “Adjuvant Approaches to Immunization”
- Merck Research Conference  
West Point, Pennsylvania – March 25, 2002
  - a) “Therapeutic Strategies for Induction of T-cell Tolerance”
- North Carolina Academy of Family Physicians Spring Symposium  
Charleston, South Carolina – April 19, 2002
  - a) “New Approaches to Allergic Rhinitis”
  - b) “Rational Approaches to Asthma Therapy”

- 17<sup>th</sup> Annual Frontiers in Research and Clinical Management of Asthma and Allergy Symposium  
Baltimore, Maryland – April 26 -April 28, 2002
  - a) “Specific Immunotherapy with DNA Constructs: Oligonucleotides Conjugated to Allergen”
  - b) “Positioning of Leukotriene Receptor Antagonists in Rhinitis”
  - c) “New Twists on Inhaled Steroid Therapy”
- University of Kentucky Internal Medicine Grand Rounds  
Lexington, Kentucky – May 22, 2002
  - a) “Therapeutic Paradigm for the Management of Allergic Rhinitis”
- 10<sup>th</sup> International Paul-Ehrlich-Seminar  
Lübeck, Germany – October 2-5, 2002
  - a) “Specific Immunotherapy with CpG – Protein Conjugates”
- 24<sup>th</sup> Symposium of the Collegium Internationale Allergologicum  
Southampton, Bermuda – November 1-6, 2002
  - a) “Immunotherapy with Immunostimulatory Oligonucleotides Linked to Purified Ragweed Amb a 1 Allergen: Effects on Nasal Allergen Provocation, Antibody Production, and Seasonal Rhinitis Endpoints”

### 2003

- American Academy of Allergy, Asthma, and Immunology  
Denver, Colorado – March 7-12, 2003
  - a) Seminar: “Optimizing Immunotherapy: Standardized Allergens/ New Adjuvants/DNA Constructs”
  - b) Workshop: “Clinical Applications of Novel Immunotherapy Techniques for Prevention of Allergic Reactions”
  - c) Symposium: “Optimal Dosing of Allergen Vaccines”
- Johns Hopkins University Immunology Council Seminar  
Baltimore, Maryland – April 15, 2003
  - a) “New Methods of Immunotherapy in Asthma and Allergic Rhinitis”
- Johns Hopkins University School of Medicine Town Meeting  
Baltimore, Maryland - June 12, 2003
  - a) Research Report – “Progress in Fighting Allergies”
- World Allergy Organization Congress – XVIII International Congress of Allergy and Clinical Immunology  
Vancouver, Canada – September 7 – 12, 2003
  - a) Symposium: “Clinical Consideration of Leukotriene Modifiers in Treatment of Rhinitis”
  - b) Workshop: “Immunotherapy: Who Gets It, How and for How Long”
  - c) Seminar: “Immunotherapy for Asthma”
- American College of Allergy, Asthma and Immunology Annual Meeting  
New Orleans, Louisiana - November 11, 2003
  - a) Plenary Session: “Immunotherapy: Why Does it Work and How”
- Genentech Special Seminar  
South San Francisco, California – November 24, 2003
  - a) “New Approaches to Vaccine Development for Allergic Respiratory Diseases”
- Austrian Society for Allergology and Immunology – OGAI Annual Meeting  
Salzburg, Germany – December 4 - 6, 2003
  - a) Keynote Symposium Address: “CpG – Allergen Conjugates”

**2004**

- Thomas Jefferson University Medicine Grand Rounds  
Philadelphia, Pennsylvania – February 26, 2004  
a) Update 2004: “Managing Asthma”
- University of Pennsylvania Allergy and Clinical Immunology Divisional Conference  
Philadelphia, Pennsylvania – February 27, 2004  
a) “Advances in Allergy Treatment”
- American Academy of Allergy, Asthma and Immunology  
San Francisco, California – March 19-23, 2004  
a) Course: “Allergen Immunotherapy Indications: Review of Efficacy Studies”  
b) Workshop: “Future Immunotherapy Treatment”  
c) Seminar: “Optimizing Immunotherapy: Standardized Allergens/New Adjuvants/DNA Constructs”
- Johns Hopkins University Medicine Grand Rounds  
Baltimore, Maryland – April 2, 2004  
a) “Progress in Vaccine Development for Allergic Diseases: Clinical Trials in Human Subjects with Immunostimulatory DNA [CpG Oligonucleotide Conjugated to Ragweed Allergen]”
- National Heart & Lung Institute and Royal Brompton Hospital  
Basic & Clinical Allergy Course  
London, England - April 19-22, 2004  
a) “Allergic Inflammation and Immunomodulation: CpG Approach”
- ALK ABELLÓ – The 5<sup>th</sup> Symposium on Specific Allergy  
London, England – April 22-24, 2004  
a) “CpG Adjuvants”
- 18<sup>th</sup> Annual Frontiers in Research and Clinical Management of Asthma and Allergy Symposium  
Baltimore, Maryland – April 30-May 2, 2004  
a) “Update on Immunotherapy for Asthma”  
b) “Allergen Vaccination with Immunostimulatory DNA: Clinical Trials in Ragweed”

**X Teaching:****Classroom Instruction:****Departmental/University:**

- a) Human Pathophysiology Course [1989-present; yearly course]  
Third quarter lecture series teaching assignment

**Divisional:**

- a) New Fellows Orientation Course [July-September] [yearly since 1987]  
Course Co-Director  
Specific Lectures: [given by me each year]
  - a) Workup of the allergic patient
  - b) Prevalent/relevant aeroallergens
  - c) Pathophysiology and treatment of allergic/non-allergic rhinitis
  - d) Diagnosis and treatment of asthma
  - e) Use of immunotherapy for allergic rhinitis
  - f) Use of immunotherapy for allergic asthma
  - g) How to prescribe and prepare immunotherapy solutions
  - h) Bronchoprovocation techniques practicum
  - i) Skin test techniques practicum

- b) Weekly Clinical Fellow Conference
  - a) Preceptor for Clinical Case Conference [monthly]
  - b) Preceptor for Clinical Topics [bi-monthly]
- c) Tutorials
  - Lectures on various topics in allergic disease for rotating residents from the Department of Medicine

### **Clinical Instruction [Clinical Teaching Responsibilities]:**

#### University/College:

- a) School of Medicine Medical Student Preceptor
  - Teaching responsibility for one medical student for one clinic session/week
  - Departmental:
- b) Department of Medicine House Staff Clerkship Rotation
  - Responsible for clinic teaching for, on average, one resident/month rotating on an elective basis through our service [5 residents rotate through 3 services during each period: Jul-Aug, Nov-Jun]

#### Divisional

- a) Allergy Clinic Preceptor
  - Three (3) clinic sessions per week with teaching responsibility for 1-2 fellows-in-training per session
- b) Allergy and Clinical Immunology Consult Attending
  - Duties for two months out of each year

### **Continuing Medical Education Instruction:**

#### Divisional:

- a) Course Director [1988 - present]
  - Frontiers in Research and Clinical Management of Asthma & Allergy Symposium. Yearly 3-day didactic course for allergists, pulmonologists, otolaryngologists, internists and primary care physicians who are actively engaged in clinical management and in research of asthma and allergic diseases.

### **MENTORING (POSTDOCTORAL):**

#### Advisees

1993 - 1995	Ana Maria G. Pasatiempo, M.D. Postdoctoral Clinical Fellow Department of Medicine, Division of Allergy and Clinical Immunology Johns Hopkins University School of Medicine Current Position: Private Practice in Allergy Instructor in Medicine (Part-time) Johns Hopkins University School of Medicine Division of Allergy and Clinical Immunology
1993 - 1995	Surender K. Vaswani, M.D. Postdoctoral Clinical Fellow Department of Medicine, Division of Allergy and Clinical Immunology Johns Hopkins University School of Medicine Current Position: Private Practice in Allergy with the Kaiser Permanente Health Care System

- 1995 - 1996 Michael Goldman, M.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine  
Current Position: Private Practice in Allergy  
Instructor in Medicine (Part-time), Johns Hopkins University  
School of Medicine, Division of Allergy and Clinical Immunology
- 1997 - 1998 Mitchell H. Grayson, M.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine  
Current Position: Instructor in Medicine, University of Washington,  
St. Louis, Missouri
- 1998 - 2000 Michele Columbo, M.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine  
Current Position: Private Practice in Allergy with Pappano, Rohr  
Bryn Mawr, Pennsylvania
- 1999 - 2001 Huamin Li, M.D., Ph.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine  
Current Position: Private Practice in Allergy  
Washington, DC
- 2001 - 2003 Sebastian Lighvani, M.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine  
Current Position: Private Practice in Allergy  
New York, NY
- 2002 - 2004 Mark Scarupa, M.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine
- 2003 - Abhilash Vaishnav, M.D.  
Postdoctoral Clinical Fellow  
Department of Medicine, Division of Allergy and Clinical Immunology  
Johns Hopkins University School of Medicine

## **XI Current Clinical Activities:**

### **Responsibilities:**

- As Clinical Director of the Division of Allergy and Clinical Immunology, responsible for the day to day medical and administrative activities of the clinical care units [10 physicians/16 clinic slots/1 nurse/2 allergy technicians] of the Section of Asthma and Allergic Diseases at the Johns Hopkins Asthma and

Allergy Center and its satellites [Johns Hopkins Greenspring Station and Johns Hopkins Hospital].

- As a Director of the Clinical Research Unit, responsible for the cohesive operation of the clinical research components of the Division of Allergy and Clinical Immunology.

### **Service Responsibilities:**

- Clinic sessions [3/week]; 1984 - present  
 Tuesday 8:00 a.m. - 1:00 p.m.  
 Tuesday 1:00 p.m. - 5:30 p.m.  
 Thursday 3:30 p.m. - 8:30 p.m.
- Inpatient consultation service attending  
 Two months/year; 1984 – present

## **XII Research Grant Participation:**

### **Major Clinical Interests and Responsibilities:**

Major focus of work has been in understanding the pathophysiology and evaluating the therapeutic effects of immunotherapy and pharmacotherapy in treating allergic rhinitis and asthma.

Extensive experience utilizing the techniques of nasal challenge and bronchial challenge to characterize the disease state and evaluate the effects of pharmacologic and immunologic manipulation on the allergic diathesis.

Development, design, conduct, and analysis of numerous clinical studies in patients with allergic rhinitis and/or asthma.

### **A. NIH/GOVERNMENT SUPPORTED GRANTS:**

- |           |  |
|-----------|--|
| 1994      | Immunotherapy in Adult Asthma<br>National Institute of Allergy and Infectious Disease/National Institutes of Health<br>(5 year award) AIRC Research #1401A12199201 |
| 1995 – 99 | Project 1: Immunotherapy in Allergic Asthma<br>Immunologic Disease Cooperative Research Center [IDCRC] Grant<br>#AI 94021<br>Principal Investigator                |
| 2000 – 04 | NIH Contract Grant [Immune Tolerance Network Grant]:<br>Allergen ISS Conjugate (AIC): A Novel Approach for Allergen Immunotherapy<br>Principal Investigator        |
| 2001 – 05 | NIH Grant<br>Tissue-Specific Mechanisms of Allergic Inflammation<br>Co-Investigator  |
| 2004      | Immune Tolerance Network Grant:<br>Asthma Immunotherapy with a Ragweed Allergen- Immunostimulatory<br>Sequence Conjugate.<br>Co-Investigator                       |

**B. PHARMACEUTICAL SUPPORTED RESEARCH PROJECTS:****RHINITIS RELATED GRANTS:**

- 1983 RPN#83-04-05-07: A Double-Blind Randomized Comparative Study of Budesonide and Placebo in Seasonal Rhinitis  
Co-Investigator Study Period (4/83-4/84)
- 1989 RPN#89-11-01-04: The Effects of Guided Imagery (GI) upon Allergic Responses to Laboratory Exposure to Ragweed Extract  
Co-Investigator Study Period (11/89-10/90)
- 1990 RPN#90-02-02-02: Noverastine: A Double-Blind Dose Response Study in Patients with Allergic Rhinitis  
Principal Investigator Study Period (3/90-3/91)  
Sponsor: McNeil Pharmaceuticals
- 1990 RPN#AAC90-07-25-01: Safety and Efficacy of Levocabastine-D in the Treatment of Seasonal Allergic Rhinitis: Double-Blind Comparison with Levocabastine, Oxymetazoline and Placebo  
Principal Investigator Study Period (9/90-9/91)  
Sponsor: Janssen Pharmaceutica
- 1991 RPN#AAC91-06-21-01: A Double-Blind Comparison of Budesonide Dry Powder, MDI and Placebo in the Treatment of Seasonal Allergic Rhinitis  
Principal Investigator Study Period (8/91-8/92)  
Sponsor: Astra/Draco
- 1992 #AAC92-06-17-01: Nasacort (Triamcinolone Acetonide Nasal Aerosol) vs Hismanal (Astemizole) in Patients with Seasonal Ragweed Allergic Rhinitis  
Principal Investigator Study Period (8/92-8/93)  
Sponsor: Rhone Poulenc Rorer
- 1994 RPN#AAC94-02-01-05: The Effects of Astemizole on the Nasal Allergic Response  
Principal Investigator Study Period: (4/94-4/95)  
Sponsor: Janssen Pharmaceutica Research Foundation
- 1994 RPN#AAC94-07-12-01: Nasacort® (Triamcinolone Acetonide Nasal Aerosol) Prophylaxis II: Used Prior to the Season in Patients with Seasonal Ragweed-Induced Allergic Rhinitis  
Principal Investigator Study Period: (8/94-8/95)  
Sponsor: Rhone Poulenc Rorer
- 1994 RPN#AAC94-07-21-01: A Double-Blind Comparison of Four Doses of Rhinocort Aqua Pump Spray (Budesonide) and Placebo in the Treatment of Adults and Children with Seasonal Allergic Rhinitis  
Principal Investigator Study Period: (8/94-11/94)  
Sponsor: Astra USA, Inc.
- 1996 RPN#AAC96-08-08-02: A Double-Blind, Placebo-Controlled Crossover Comparison of Fexofenadine, Terfenadine, and Loratadine Utilizing a Skin Test Model to Examine Suppression of Histamine-Induced Wheal and Flare  
Principal Investigator Study Period: (10/96-1/97)  
Sponsor: Hoechst Marion Roussel

- 1997 RPN#AAC97-06-06-01: Effect of Ragweed Allergy and the Treatment of Allergy Symptoms with Fexofenadine HCl or Clemastine on Scholastic Assessment Test (SAT) Scores  
Principal Investigator Study Period: (7/97-7/98)  
Sponsor: Hoechst Marion Roussel
- 1997 RPN#AAC97-10-17-02: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Dose Response of Fexofenadine [60mg, 120mg, 360mg BID] on Mediator Release Following Nasal Provocation Test with Ragweed Allergen  
Principal Investigator Study Period: (11/97-3/98; ext to 7/98)  
Sponsor: Hoechst Marion Roussel
- 1998 RPN#AAC98-01-16-02: A Randomized, Double-Blind Study of Astelin Nasal Spray Monotherapy vs. Combination Therapy of a Nasal Steroid and Oral Antihistamine in Subjects with Seasonal Allergic Rhinitis  
Principal Investigator Study Period: (4/98-7/98)  
Sponsor: Wallace Laboratories
- 1998 – 99 RPN#AAC98-09-10-01: A Double-Blind Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine HCl 120 mg QD, 180 mg QD, 240 mg QD Cetirizine HCl 10 mg QD, and Placebo QD in the Treatment of Perennial Allergic Rhinitis  
Principal Investigator Study Period: (10/98-11/99)  
Sponsor: Hoechst Marion Roussel
- 1999 RPN: pending: PNU-142731: An Exploratory Multiple Oral Dose Nasal Allergen Challenge Study in Atopic Patients with Allergic Rhinitis  
Principal Investigator Study Period: (1/99-6/99)  
Sponsor: Pharmacia and Upjohn
- 2002 RPN# SAM40066: Pending: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10 mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis who are Receiving Concurrent Open-Label Advair Diskus 100/50mcg BID.  
Principal Investigator Study Period (07/01/02-07/01/03)  
Sponsor: GlaxoSmithKline

**ASTHMA RELATED GRANTS:**

- 1987 RPN#87-04-23-05: Effects of SK&F Compound 104353-Z2 in the Immediate and Late Bronchial Constrictive Response to Allergen Inhalation  
Principal Investigator Study Period: (6/87-6/88)  
Sponsor: Smith Kline & French Pharmaceuticals
- 1988 RPN#87-07-06-02: A Double-Blind Multicenter Group Comparative Study of the Efficacy and Safety of Tilade® (nedocromil sodium) versus Placebo in the Management of Adults with Reversible Airways Obstruction  
Principal Investigator Study Period: (8/87 - 8/89)  
Sponsor: Fisons Corporation
- 1991 RPN#AAC91-01-08-03: Pemirolast/Placebo Double-Blind, Randomized, Parallel Group Study of Patients with a History of Chronic, Stable, Reversible Asthma Requiring Bronchodilator Therapy  
Principal Investigator Study Period: (1/91 - 1/92)

Sponsor: Bristol Myers Squibb

- 1991 RPN#AAC91-07-19-01: A Multicenter, Double-Blind, Double Dummy, Placebo-Controlled, Group-Comparative Study of the Safety and Effective-ness of Four Dose-Levels of Tipredane as Compared to Beclomethasone Dipropionate in the Treatment of Adults with Moderate Asthma  
Principal Investigator Study Period: (9/91 - 9/92)  
Sponsor: Fisons Pharmaceuticals
- 1993 RPN#AAC93-10-21-01: A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled Group Comparative Study of the Safety and Effectiveness of Four Dose-Levels of Tipredane as compared to a Beclomethasone Dipropionate in the Treatment of Adults with Moderate Asthma (Project #1900)  
Principal Investigator Study Period: (8/92 - 8/93)  
Sponsor: Fisons Pharmaceuticals
- 1993 RPN#AAC93-04-01-02: Phase III Study of the Effects of Zileuton vs. Placebo on Bronchial Hyperresponsivity in Asthma Patients  
Principal Investigator Study Period: (6/93-5/94)  
Sponsor: Abbott Pharmaceutical
- 1993 RPN#AAC93-10-21-01: A 12-Week Placebo-Controlled Study of Albuterol Turbuhaler, 50  $\mu$ g and 100  $\mu$ g Administered Four Times Daily, in Patients with Reversible Obstructive Airway Disease  
Principal Investigator Study Period: (12/93-12/94)  
Sponsor: Astra USA, Inc.
- 1994 RPN#AAC94-02-17-02: A Bronchoprovocation Study Comparing 2 Formulations of Albuterol Metered-Dose Aerosol Inhaler in Patients with Mild to Moderate Asthma  
Principal Investigator Study Period: (4/94-4/95)  
Sponsor: A. L. Laboratories (Pharmakinetics)
- 1994 RPN#AAC94-09-09-02: Safety Evaluation of Two Formulations of Albuterol Metered Dose Aerosol Inhaler in Healthy Volunteers  
Principal Investigator Study Period: (11/94-4/95)  
Sponsor: A. L. Laboratories, Inc. (Pharmakinetics)
- 1995 RPN#AAC95-10-06-04: Bronchoprotective Effects of Azmacort (triamcinolone acetonide) vs Serevent (salmeterol xinafoate) vs the Combination in Patients with Asthma  
Principal Investigator Study Period: (10/95-10/96)  
Sponsor: Rhone-Poulenc Rorer
- 1996 RPN#AAC95-11-27-04: A Comparison of the Safety and Efficacy of Two Oral Doses of PDA-641 (10 mg and 30 mg TID) and Placebo in Mild to Moderate Asthmatics (Protocol No. 0805A-205-US)  
Principal Investigator Study Period: (2/96-2/97)  
Sponsor: Wyeth-Ayerst Research
- 1996 RPN#AAC96-04-08-01: Iralukast vs Placebo in Patients with Mild to Moderate Asthma  
Co-investigator Study Period: (5/96-9/96)  
Sponsor: Ciba-Geigy Corporation
- 1996 RPN# Protocol SD-004-0111: START-Inhaled Steroid Treatment As Regular Therapy in Early Asthma. A Study of the Effect of Early Intervention With Long-

Term Inhaled Budesonide (Pulmicort® Turbuhaler®) in Newly Diagnosed Asthma  
 Principal Investigator Study Period: (10/96-10/99)  
 Sponsor: Astra, USA

1997 RPN#AAC97-01-24-01: A Six-week Dose Response Study of RPR 106541T in 10, 50 and 400 mcg BID Versus Beclomethasone Dipropionate 168 mcg BID Versus Placebo in Chronic Asthma  
 Principal Investigator Study Period: (3/97-3/98)  
 Sponsor: Rhone-Poulenc Rorer

1997 RPN#AAC97-06-19-01: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Effect of Montelukast Sodium Compared to Inhaled Beclomethasone Dipropionate in Adult Asthmatics  
 Principal Investigator Study Period: (8/97-8/98)  
 Sponsor: Merck & Co., Inc.

1997 RPN#AAC97-06-24-01: A Randomized, Placebo-Controlled, Dose Response Study of Albuterol Sulfate Administered by the Inhale Therapeutic Systems Pulmonary Delivery System: Methacholine Challenge  
 Principal Investigator Study Period: (8/97-8/98)  
 Sponsor: Inhale Therapeutic Systems

1997 RPN#AAC97-09-10-01: A 12-week, Multi-Center, Double-Blind, Parallel Group Comparison of the Safety and Efficacy of Pranlukast 300 mg Twice Daily with Placebo in Patients with Asthma  
 Principal Investigator Study Period: (10/97-3/98)  
 Sponsor: SmithKline Beecham

1998 RPN# AAC98-10-16-01: A Randomized, 24-week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Ariflo [15 mg BID] in Patients with Chronic Obstructive Pulmonary Disease [COPD]  
 Principal Investigator Study Period: (11/98-11/99)  
 Sponsor: SmithKline Beecham

1999 RPN#AAC95-10-06-03: A Dose Response Comparative Study of Inhaled Corticosteroid in Asthmatic Subjects  
 Principal Investigator Study Period: (5/99-11/99)  
 Sponsor: Glaxo

1999 RPN# AAC99-09-24-01: A Study To Compare The Consistency Of Dosing Efficacy With Proventil HFA vs. Proventil MDI: Used After Various Periods Of Resting Without Priming  
 Principal Investigator Study Period: (1/1/00-12/31/00)  
 Sponsor: Schering Plough Corporation

1999 RPN# AAC99-06-25-01: A Study to Compare the Effects of Low Temperatures on the Clinical Performance of Proventil-HFA-MDI in Asthmatic Subjects  
 Principal Investigator Study Period: (12/27/99 – 5/31/00)  
 Sponsor: Schering Plough Corporation

1999 RPN#AAC99-09-10-06-01: A Double-Blind Randomized Controlled Study of DISKUS Combo vs. FP 100mcg vs. SMT 50mcg in Asthma  
 Principal Investigator Study Period: (11/15/99 – 11/15/00)  
 Sponsor: Glaxo Wellcome, Inc.

- 1999 RPN#AAC99-12-10-01: A Randomized, Double-Blind, Parallel-Group Trial Assessing The Efficacy And Safety Of Fluticasone Propionate Inhalation Powder (250 Mcg QD) And Placebo In Subject Greater Than 12 Years Of Age With Chronic Asthma.  
Principal Investigator Study Period: (12/03/99 – 12/03/00)  
Sponsor: Glaxo Wellcome, Inc.
- 1999 RPN# AAC99-09-10-03: A Randomized, Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ariflo [15mg BID] in patients with Chronic Obstructive Pulmonary Disease.  
Principal Investigator Study Period: (10/1/99 – 9/30/00)  
Sponsor: SmithKline
- 2000 RPN#AAC00-02-16-02: A Randomized, Double-Blind, Parallel-Group Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg DISKUS Inhaler BID vs. Fluticasone Propionate 250mcg via DISKUS Inhaler BID in Adolescents and Adults with Moderate Persistent Asthma.  
Principal Investigator Study Period: (2/14/00- 6/07/02)  
Sponsor: Glaxo Wellcome, Inc.
- 2000 RPN#AAC00-02-29-01: A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Pilot Study to Observe the Effects of Montelukast 10mg in Combination with Fexofenadine 180mg Daily or 120mg BID on Asthma in Subjects with Persistent Mild to Moderate Atopic Asthma  
Principal Investigator Study Period: (5/1/00 – 10/31/00)  
Sponsor: Aventis Pharmaceuticals Inc.
- 2001 RPN# AAC99-09-10-03: A Randomized, Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ariflo [15mg BID] in patients with Chronic Obstructive Pulmonary Disease.  
Principal Investigator Study Period: (10/01/00– 9/01/02)  
Sponsor: GlaxoSmithKline
- 2001 RPN#AAC01-05-18-01: A Phase III Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100µg/Day, 200µg/Day, and 400µg/Day (Ex-Valve) Administered Once Daily for 12-Weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.  
Principal Investigator Study Period (01/10/01-10/30/02)  
Sponsor: Aventis Pharmaceuticals Inc.
- 2002 RPN# SAS40066: A Randomized, Open-Label, Crossover Pilot Trial, Assessing Patient Preference for ADVAIR DISKUS 100/50 BID (Fluticasone Propionate/Salmeterol Combination Product 100/50 mdg versus SINGULAIR (Montelukast 10 mg) in Subjects ≥15 years of age with Persistent Asthma  
Principal Investigator Study Period (12/10/01-05/01/02)  
Sponsor: GlaxoSmith Kline
- 2002 RPN# 16455P/3001: A Multicenter, Double-Blind, Randomized, Parallel Groups, Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects with Mild to Moderate Persistent Asthma.  
Principal Investigator Study Period (07/01/02-07/09/03)  
Sponsor: Aventis Pharmaceuticals Inc.

- 2002 RPN# 16455P/3003: A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects with Asthma.  
Principal Investigator Study Period (07/01/02-10/14/03)  
Sponsor: Aventis Pharmaceuticals, Inc.
- 2004 RPN# 04-10-25-03: Effect of Anti-IgE in Non-Allergic Asthma.  
Principal Investigator Study Period (12/27/04- )  
Sponsor: Novartis Pharmaceuticals

**IMMUNOTHERAPY RELATED GRANTS:**

- 1986 RPN#86-09-29-04: A Double-Blind Safety Comparison Study of Polygen Ragweed [Polymerized, Modified Ragweed Allergenic Extract Mix (Short-Giant Ragweed)] versus a Conventional Extract Mix (Short/Giant Ragweed) in the Treatment of Seasonal Allergic Rhinitis  
Principal Investigator Study Period: (10/86 - 8/88)  
Sponsor: ALO/Key Pharmaceuticals
- 1987 RPN#87-08-05-01: A Double-Blind, Randomized Study of an Orally Administered Allergenic Extract in Adults with Seasonal Allergic Rhinitis (Ragweed Hay Fever)  
Co-Investigator Study Period: (9/87 - 9/88)  
Sponsor: Immunotec
- 1988 RPN#88-07-12-02: The Efficacy and Safety of Oralan as an Oral Desensitization Compound: Ragweed  
Principal Investigator Study Period:(7/88 - 7/89)  
Sponsor: Immunotec, Inc.
- 1989 RPN#88-07-12-02: The Efficacy and Safety of Oralan as an Oral Desensitization Compound: Ragweed [High Dose]  
Principal Investigator Study Period: (7/89 - 7/90)  
Sponsor: Immunotec, Inc.
- 1992 RPN#AAC92-02-10-02: Immunotherapy with CATVAX Peptides, Phase I  
Co-Investigator Study Period: (4/92 - 4/93)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1993 RPN#AAC93-02-10-01: Phase II Clinical Study of the Safety and Activity of Catvax  
Co-Investigator Study Period: (3/93 - 3/94)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1993 RPN#AAC93-09-09-01: Phase II Clinical Study of the Safety and Activity of CatVax in a Bronchial Allergen Challenge Model  
Principal Investigator Study Period: (10/93-10/94)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1994 RPN#AAC94-01-05-01: Phase I Clinical Study of the Safety and Activity of Allervax® Ragweed  
Principal Investigator Study Period: (2/94-1/95)  
Sponsor: ImmuLogic Pharmaceutical Corporation

- 1994 RPN#AAC94-09-19-01: A Phase II Clinical Study of the Safety and Efficacy of Allervax® Ragweed Using a Nasal Allergen Challenge Model  
Principal Investigator Study Period: (10/94-6/95)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1995 RPN#AAC95-05-08-03: A Safety and Efficacy Study of Allervax® Ragweed Using a Seasonal Model  
Principal Investigator Study Period: (6/95-11/95)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1996 RPN#AAC96-05-24-01: An Exploratory Efficacy and Safety Study of Allervax® Ragweed Peptides Using a Seasonal Model [Protocol P96-01] Revised 062796  
Principal Investigator Study Period: (6/96-2/97)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1997 RPN#AAC96-05-24-01: An Exploratory Efficacy and Safety Study of Allervax® Ragweed Peptides Using a Seasonal Model [Protocol P96-01] Revised 062796: Safety: Early and Late Adverse Reactions to Immunotherapy  
Principal Investigator Study Period: (2/97-12/97)  
Sponsor: ImmuLogic Pharmaceutical Corporation
- 1999 RPN#AAC98-12-04-02: PNU-142731: An Exploratory Multiple Oral Dose Nasal Allergen Challenge Study in Atopic Subjects with Allergic Rhinitis  
Principal Investigator Study Period: (2/99-4/99)  
Sponsor: Pharmacia & Upjohn
- 1999 RPN#AAC99-04-05-01: A Phase I, Open-Label, Single Center Study to Explore the Safety & Tolerability of Dynavax *Amb a 1* Immunostimulatory Oligonucleotide Conjugate (AIC) When Administered by a Quantitative Intradermal Procedure to Healthy Adults who are Ragweed Allergic.  
Principal Investigator Study Period: (5/3/99-11/2/99)  
Sponsor: Dynavax Technologies Corporation
- 1999 RPN#AAC98-12-29-01: Effect of Modified Rush [Cluster] Immunotherapy on Cellular and Immunologic Parameters  
Principal Investigator Study Period: (4/99-10/99)  
Sponsor: Dynavax Technologies Corporation
- 2000 RPN#AAC99-04-12-01: A Phase I, Single-Blind, Randomized, Placebo-Controlled, Single-Center Study to Explore the Safety, Tolerability and Immunogenicity of Dynavax *Amb a 1* Immunostimulatory Oligonucleotide Conjugate (AIC) in Healthy Adults Who are Ragweed Allergic.  
Principal Investigator Study Period: (6/15/00- ongoing)  
Sponsor: Dynavax Technologies Corporation
- 2000 RPN#AAC99-09-10-04: Safety and Immunogenicity of Orally Administered Encapsulated Short Ragweed Pollen Extract (Sponsor's Protocol ASR 07)  
Principal Investigator Study Period: (2/4/00-12/31/00)  
Sponsor: Allergens, Inc.
- 2001 RPN#AAC00-06-30-02: A Phase I, Open-Label, Single Center Study to Explore the Safety and Tolerability of a New clinical Lot of Dynavax *Amb a 1* Immunostimulatory Oligonucleotide Conjugate (AIC) When Administered by a Quantitative Intradermal Procedure to Healthy Adults Who are Ragweed Allergic.  
Principal Investigator Study Period: (4/21/00-8/1/01)  
Sponsor: Dynavax Technologies Corporation

- 2002 RPN# Follow-on: Treatment of Allergic Rhinitis with Ragweed Allergen Conjugated to an Immunostimulatory DNA Sequence  
Principal Investigator Study Period: (9/01/02-12/31/03)  
Sponsor: Dynavax Technologies Corporation
- 2003 RPN# AAC03-09-30-01: A Phase I, Observer-Blind, Randomized, Placebo-Controlled Study of the Tolerability and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults Protocol DV1-Sar-05.  
Principal Investigator Study Period: (9/24/03- )
- 2004 RPN# pending: A Phase IIb, Observer-Blind, Randomized, Placebo-Controlled Study of the Tolerability and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults Protocol DV1-Sar-06.  
Principal Investigator Study Period: (4/01/04- )

### EDUCATIONAL RELATED GRANTS;

Recipient of educational grants to develop preceptorship programs for training of both physicians and pharmaceutical representatives:

#### Physician Preceptorship Programs:

Preceptorship Program developed for primary care physicians involved in the management of patients with allergic respiratory problems. Program comprised of both didactic and clinical observation components. Goals of program are to provide participants with an in-depth understanding of the approach that our specialty takes in evaluating, diagnosing, and treating patients with allergic diseases.

Sponsors: GlaxoWellcome (1997-1998)  
World WIT (2000-2001)

#### Pharmaceutical Representative/Scientific Specialists Preceptorship Programs:

Preceptorship Program developed based on a perceived need within the pharmaceutical industry for a mechanism to educate pharmaceutical representatives. Program goals geared toward providing pharmaceutical representatives with a more in-depth understanding of the approach that our specialty takes in evaluating and treating patients with allergies and asthma. Funded through grants.

Sponsors: GlaxoSmithKline (1997-2003)  
AstraZeneca (1999-2002)  
Merck (1999-2000)

## XIII: PUBLICATIONS

### PEER-REVIEWED SCIENTIFIC ARTICLES:

1. Graber, CD, **Creticos, PS**, et al. T mycoplasma in human reproductive failure. **Obstetrics and Gynecology**. 54(5), November, 1979.
2. **Creticos, PS**, Van Metre, TE, Mardiney, GL, Norman, PS, Adkinson, NF Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. **J. Allergy Clin. Immunol.** 73:94-104, 1984.

3. **Creticos, PS**, Peters, SP, Adkinson, NF Jr., Naclerio, RM, Hayes, EC, Norman, PS, Lichtenstein, LM. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. **New Engl. J. Med.** 310:1626-1630, 1984.
4. Naclerio, RM, Proud, D, Togias, AG, Kagey-Sobotka, A, Peters, SP, **Creticos, PS**, Adkinson, NF Jr, Norman, PS, Lichtenstein, LM. Mediators in nasal secretions of patients with allergic rhinitis. **Immunol. Allergy Prac.** VII(6):212/25-32/219. June, 1985.
5. **Creticos, PS**, Adkinson, NF Jr, Kagey-Sobotka, A, Proud, D, Meier, HL, Naclerio, RM, Lichtenstein, LM, Norman, PS. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. **J. Clin. Invest.** 76:2247-2253, 1985.
6. **Creticos, PS**, Marsh, DG, Proud, D, Kagey-Sobotka, A, Adkinson, NF Jr, Friedhoff, L, Naclerio, RM, Lichtenstein, LM, Norman, PS. Responses to ragweed pollen nasal challenge before and after immunotherapy. **J. Allergy Clin. Immunol.** 84:197-205, 1989.
7. Norman, PS, **Creticos, PS**, Marsh DG. Frequency of booster injections of ragweed allergoids. **J. Allergy Clin. Immunol.** Vol. 85 (No.1, Part 1): 88-94, January, 1990.
8. Iliopolous, O, Proud, D, Adkinson, NF Jr, **Creticos, PS**, Norman, PS, Kagey-Sobotka, A, Lichtenstein, LM, Naclerio, RM. Effects of immunotherapy on the early, late and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. **J. Allergy Clin. Immunol.** 87:855-866, 1991.
9. Furin, MJ, Norman, PS, **Creticos, PS**, Naclerio, RM. Immunotherapy decreases antigen-induced eosinophils migration into the nasal cavity. **J Allergy Clin. Immunol.** 88:27-32, 1991.
10. Majchel, AM, Proud, D, Freidhoff, L, **Creticos, PS**, Norman, PS, Naclerio, RM. The nasal response to histamine challenge: Effect of the pollen season and immunotherapy. **J. Allergy Clin Immunol.** 90:85-91, 1992.
11. Norman, PS, **Creticos, PS**, Tobey, R, Proud, DG, Kagey-Sobotka, A, Meyers, DA, Persson, T. Budesonide in grass pollen rhinitis. **Ann Allergy.** 69:309-316, 1992.
12. Naclerio, RM, Adkinson, NF Jr, **Creticos, PS**, Baroody, FM, Hamilton, RG, Norman, PS. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. **J. Allergy Clin Immunol.** 92:717-21, 1993.
13. Cohen, RE, **Creticos, PS**, Norman, PS. The effects of guided imagery (GI) on allergic subjects' responses to ragweed-pollen nasal challenge: An exploratory investigation. **Imagination, Cognition and Personality.** Vol. 13 (3):259-269, 1993-94.
14. **Creticos, PS**, Burk, J, Smith, L, Comp, R, Norman, PS, Findlay, S. The use of twice daily nedocromil sodium in the treatment of asthma. **J. Allergy Clin. Immunol.** 95:829-836, 1995.
15. Vaswani, SK, Mawhorter, SD, **Creticos, PS**. An unusual case of asthma with onset late in life. **Annals of Allergy, Asthma, & Immunology.** Vol 75: August, 1995.
16. **Creticos, PS**, Reed, CE, Norman, PS, Khoury, J, Adkinson, NF Jr, Buncher, CR, Busse, WW, Bush, RK, Gadde, J, Li, JT, Richerson, HB, Rosenthal, RR, Solomon, WR, Steinberg, P, Yunginger, JW. Ragweed immunotherapy in adult asthma. **N Engl J Med.** 334(8):501-6, 1996.
17. Bernstein, DI, **Creticos, PS**, Busse, WW, Cohen, R, Graft, DF, Howland, WC, Lumry, WR, Pedinoff, AJ, Ratner, PH, Lim, J, Stokes, A, McNally, C. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed allergic rhinitis. **J. Allergy Clin. Immunol.** 97:749-55, 1996.

18. Norman, PS, Ohman, JL Jr, Long, AA, **Creticos, PS**, Gefter, MA, Shaked, Z, Wood, RA, Eggleston, PA, Hafner, KB, Rao, P, Lichtenstein, LM, Jones, NH, Nicodemus, CF. Treatment of cat allergy with T cell epitope containing peptides. **Am J. Respir Crit Care Med.** 154(6 Pt.1):1623-8, December, 1996.
19. **Creticos, PS**. Effects of nedocromil sodium on inflammation and symptoms in therapeutic studies. **J Allergy Clin Immunol.** 98 (5) 2: S143-S150. 1996.
20. Naclerio RM, Proud D, Moylan B, Balcer S, Freidhoff L, , Kagey-Sabotka A. Lichtenstein LM, **Creticos, PS**, Hamilton R, Norman PS, A Double Blind Study of the Discontinuation of Ragweed Immunotherapy. **J. Allergy Clin Immunol.** 101(3): 293-300. 1998.
21. Laube, BL, Edwards AM, Dalby Rn, **Creticos, PS**, Norman, PS. The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. **J. Allergy Clin. Immunol.** 101 (4) :475-483, 1998.
22. **Creticos, PS**, Fireman, P, Settipane, G, Bernstein, D, Casale ,T, Schwartz, H and Rhinocort Aqua Study Group. Intranasal Budesonide Aqueous Pump Spray (Rhinocort® Aqua) for the Treatment of Seasonal Allergic Rhinitis. **Allergy and Asthma Proceedings.** Vol 19 (No.5): 285-294. September-October, 1998.
23. Tighe, H, Takabayashi, K, Schwartz , D, Van Nest, G, Tuck, S, Eiden , JJ, Kagey-Sobotka, A, **Creticos, PS**, Lichtenstein, LM, Spiegelbert, HL, Raz, E. Conjugation of Immunostimulatory DNA to the Short Ragweed Allergen Amb a 1 Enhances Immunogenicity and Reduces its Allergenicity. **J. Allergy and Clin Immun.** 106:(1Pt 1):124-34; July 2000.
24. Marshall, JD, Abrahi, S, Eiden, JJ, Tuck, S, Milley, R, Haycock, F, Reid, M, Kagey-Sobotka, A, **Creticos, PS**, Lichtenstein, LM, Van Nest, G. Immunostimulatory Sequences (ISS) DNA Linked to Amb a 1 Allergen Promotes Th1 Cytokine Expression while Downregulating Th2 Cytokine Expression in PBMC's from Ragweed-Allergic Humans. **J Allergy and Clinical Immunol.** 108; 191-97, 2001.
25. **Creticos, PS**, Knobil, K, Edwards, L, Richard, K, Dorinsky, P. Loss of Response to Treatment with Leukotriene Receptor Antagonists but not Inhaled Corticosteroids in Patients over 50 Years of Age. **Annals of Allergy, Asthma & Immunology.** Vol 88 401-409; April 2002.
26. **Creticos, PS**, Petty, BG, Khattignavong, AP, Lewis, LD, Lietman, PS, Adams, WP, Singh, GJ, Molzon, JA, Martinex, MN, Williams, RL. Development of Pharmacodynamic Methodology for Determination of Albuterol Metered Dose Inhaler In Vivo Bioequivalence: Methacholine Challenge Study. **J Allergy and Clin Immun.** Vol 110 (5) 713-720; November 2002.
27. Busse, W, Koenig, S, Oppenheimer, J, Sahns, Yancey, S, Reilly, D, Edwards, L, Dorinsky P, **Creticos, PS** (contributing author). Steroid -sparing Effects of Fluticasone Propionate 100 $\mu$ g and Salmeterol 50 $\mu$ g Administered Twice Daily in a Single Product in Patients Previously Controlled with Fluticasone Propionate 250 $\mu$ g Administered Twice Daily. **J. Allergy Clin Immunol.** Vol 111 (1) 57-65 January 2003.
28. Chen YH, Bieneman AP, Creticos PS Chichester KL, Schroeder JT, IFN-alpha Inhibits IL-3 Priming of Human Basophil Cytokine Secretion but not Leukotriene C4 and Histamine Release. **J. Allergy Clin. Immunol.** 112, No 5, 944-50 (3) Nov. 2003.

- 29 Balcer-Whaley, SL, Eiden, JJ, Kagey-Sobotka, A, Hamilton R, Van Nest, G, **Creticos, PS.** Safety and Tolerability of an *Amb a 1* Immunostimulatory Oligodeoxynucleotide Conjugate (AIC) Administered By a Quantitative Intradermal Procedure to Adults Allergic to Ragweed. **Annals of Allergy.** (in press) 2004.
30. **Creticos, PS,** Schroeder, JT, Broide, D, Balcer-Whaley, SL, Khattignavong, A, Li, H, Hamilton, RG, Seyfert, V, Eiden, JJ. Immunotherapy with an Amb a 1 Immunostimulatory Oligodeoxynucleotide Conjugate: A New Paradigm in the Treatment of Allergic Disease. **NEJM.** (submitted) 2004.
31. **Creticos, PS,** Schroeder, JT, Chen Y. New Approaches in Immunotherapy: Allergen Vaccination with Immunostimulatory DNA. **Immunology and Allergy Clinics of North America.** Vol. 24; 569-581. November 2004.

#### INVITED REVIEW ARTICLES IN PEER-REVIEWED JOURNALS:

32. Peters, SP, **Creticos, PS,** Naclerio, RM, Schleimer, RP, MacGlashan, DW Jr, Adkinson, NF Jr, Norman, PS, Lichtenstein, LM. IgE-mediated leukotriene release *in vitro* and *in vivo*. **Trans. Assn. Am. Phys.** XCVII:260-267, 1984.
32. Norman, PS, Naclerio, RM, **Creticos, PS,** Togias, A, Lichtenstein, LM. Mediator release after allergic and physical nasal challenges. **Int. Arch. Allergy Appl. Immunol.** 77:57-63, 1985.
34. Schleimer, RP, Fox, CC, Naclerio, RM, Plaut, M, **Creticos, PS,** Togias, AG, Warner, JA, Kagey-Sobotka, A, Lichtenstein, LM. Role of human basophils and mast cells in the pathogenesis of allergic diseases. **J. Allergy Clin. Immunol.** 76:369-374, 1985.
35. Togias, A, Naclerio, RM, Proud, D, Baumgarten, C, Peters, SP, **Creticos, PS,** Warner, J, Kagey-Sobotka, A, Adkinson, NF Jr, Norman, PS, Lichtenstein, LM. Mediator release during nasal provocation: a model to investigate the pathophysiology of rhinitis. **Am. J. Med.** 79: 26-33, 1985.
36. **Creticos, PS,** and Norman, PS. Why standardized extracts are necessary. **Clinical Reviews in Allergy.** 4 (No.4): 355-361, Nov, 1986.
37. **Creticos, PS,** and Norman, PS. Immunotherapy with Allergens. **JAMA: Primer on Allergic and Immunologic Diseases.** 258 (No.20): 2874-2880, Nov, 1987.
38. **Creticos, PS,** Norman, PS. Immunotherapy with Allergens. **JAMA, Chinese Edition:** Vol 7, Issue 3: 170-171, June, 1988.
39. **Creticos, PS.** Inflammation in Asthma: Immunotherapy in asthma. **J. Allergy Clin. Immunol.** 83:554-62, 1989.
40. **Creticos, PS.** The Use of Standardized Extracts in Allergy Practice. **Immunology & Allergy Practice.** Vol. XI (No.8): 37-38, August 1989.
41. **Creticos, PS.** The role of cromolyn sodium in allergic rhinitis. **J. Resp. Dis.** Supplement, S18-S21: November 1989.
42. **Creticos, PS.** The clinical implications of the inflammatory component of allergic respiratory tract disease: A case study. **ACI News.** Vol. 2 (No.2): 50-53: March/April 1990.

43. Alvarez Cuesta, E, Creticos, P, Horak, H, Negro, JM, Rak, S, Zeiss, R. Seguimiento de laInmunoterapia - Symposium Internacional de Inmunoterapia, Madrid, 26-29 Abril 1989. **Rev Esp Alergol Immunol Clin.** Vol. 6, Suplemento num. 1, pp. 115-128; Marzo 1991.
44. **Creticos, PS.** Efficacy of immunotherapy in allergic rhinitis. **J. Resp. Dis.** Vol. 12, No. 3 Supplement, S43-S45; March 1991.
45. **Creticos, PS.** Immunologic changes associated with immunotherapy. Immunotherapy of IgE-mediated Disorders. **Immunology and Allergy Clinics of North America.** 12 (1):13-37, 1992.
46. **Creticos, PS.** The role of antihistamines in allergic rhinitis. **J. Resp. Dis.** Vol. 13, No. 8 Supplement, S21-S29; August 1992.
47. **Creticos, PS.** Immunotherapy with allergens. **JAMA: Primer on Allergic and Immunologic Diseases.** 268 (20):2834-2839, Nov., 1992.
48. **Creticos, PS.** The role of immunotherapy in allergic rhinitis/allergic asthma. **Allergy Proceedings.** 16 (6):297-302, Nov.-Dec., 1995.
49. **Creticos, PS.** Effects of nedocromil sodium on inflammation and symptoms in therapeutic studies. **J. Allergy Clin. Immunol.** Supplement, 98:S143-50, 1996.
50. Vaswani, SK, **Creticos, PS.** Metered Dose Inhaler: Past, Present, and Future. **Annals of Allergy, Asthma, & Immunology.** 80(1):11-9; quiz 19-20. Review January, 1998.
51. Bousquet J, Lockey R, Malling HJ, **Creticos PS** et al. Allergen Immunotherapy: Therapeutic Vaccines for allergic diseases. WHO Position Paper. **European J of Allergy and Clin Immun.** No. 44, Vol 53, 1998.
52. **Creticos, PS.** The Consideration of Immunotherapy in the Treatment of Allergic Asthma. **J. Allergy Clin. Immunol.** No.2 Part 2 Vol 105, S559-74, Feb. 2000.
53. **Creticos, PS.** Managing Asthma in Adults. **Am J Managed Care.** 6 (17Suppl):S940-63, Oct. 2000.
54. **Creticos, PS.** The Consideration of Immunotherapy in the Treatment of Allergic Asthma. **Annals of Allergy.** 87 (Suppl 1): 13-27, Review; July 2001.
55. **Creticos, PS.** Best-Practice Strategies for Management of Asthma: Monitoring and Prevention of Asthma Exacerbations. **Advanced Studies in Medicine.** Vol 2 No 1 19-26, January 2002.
56. **Creticos, PS.** Advances in Asthma Management. **Advanced Studies in Medicine.** Vol 2 No 1 6-7, January 2002.
57. **Creticos, PS.** Clinical and Economic Factors of Combination Therapy in Asthma. **Advanced Studies in Medicine.** Vol 2, No 3; 19-26, January 2002.
58. **Creticos, PS.** New Methods of Immunotherapy in Allergic Respiratory Diseases. **Advanced Studies in Medicine.** Vol. 2 No. 7 270-274, May 2002.
59. **Creticos, PS.** Treatment Options for Initial Maintenance Therapy of Persistent Asthma: A Review of Inhaled Corticosteroid and Leukotriene Receptor Antagonists. **Drugs.** 63 Suppl 2, 1-20, 2003).
60. **Creticos, PS,** Lichtenstein, LM. Progress in the Development of New Methods of Immunotherapy: Potential Application of Immunostimulatory DNA-Conjugated to Allergens for Treatment of Allergic Respiratory Conditions. **Regulatory Control and Standardization of Allergenic**

**Extracts.** 10<sup>th</sup> International Paul-Ehrlich-Seminar; October 2-5, 2002; 304-312. Publisher: Frankfurt am Main, Druck – un Verlagshaus Sperlich, 2003

### BOOK CHAPTERS, MONOGRAPHS:

61. Adkinson, NF Jr., **Creticos, PS**, Norman, PS, Mardiney, MR, Rosenberg, GL, Hamilton, RG, Van Metre, TE. Characteristics of human IgE antibody responses *in vivo*. **Monogr. Allergy**. 18:69-74, 1983.
62. Lichtenstein, LM, Schleimer, RP, MacGlashan, DW, Jr, Peters, SP, Schulman, ES, Proud, D, **Creticos, PS**, Naclerio, RM, Kagey-Sobotka, A. *In vitro* and *in vivo* studies of mediator release from human mast cells. **In: Asthma III: Physiology, Immunopharmacology and Treatment.** (ED.: A.B. Kay) Academic Press, London, 1984.
63. **Creticos, PS**, Peters, SP. Anaphylaxis. **Clinical Studies in Medical Biochemistry.** Chapter 23:225-233. (Eds.: R.H. Glew and S.P. Peters) Oxford University Press, N.Y. 1987.
64. **Creticos, PS**, and Norman, PS. Immunotherapy in inhalant allergy. **Allergy: An International Textbook**; Edited by: M.H. Lessof, T.H. Lee, D.M. Kemeny; John Wiley & Sons Ltd.; Chichester, U.K. 1987.
65. **Creticos, PS**, Norman, PS. In vivo provocative testing for IgE-mediated disease. Lockey/Bukantz: **Allergen Immunotherapy**, Marcel Dekker, Inc. Publishers. Chapter 6:119-144, 1991.
66. **Creticos, PS**. Drug therapy of asthma. Smith & Reynard: **Textbook of Pharmacology**, W.B. Saunders Company Publishers. Chapter 62: 1051-1066, 1992.
67. **Creticos, PS**. Allergic rhinitis. **Asthma and Rhinitis**: Edited by William W. Busse and Stephen T. Holgate. Blackwell Scientific Publications. Chapter 105:1394-1414, 1994.
68. **Creticos, PS**. Efficacy Parameters. **In: Immunotherapy: A Practical Guide to Current Procedures.** Edited by P.S. Creticos. Manual sponsored by the American Academy of Allergy and Immunology. Chapter 5:1-19, 1994.
69. **Creticos, PS**. Patient education in the United States. Proceedings of the XVth International Congress of Allergology and Clinical Immunology and the 1994 Annual Meeting of the European Academy of Allergology and Clinical Immunology, Stockholm, June 26-July 1, 1994. **Progress in Allergy and Clinical Immunology.** Edited by S.G.O. Johansson. Hogrefe & Huber Publishers. Volume 3, Stockholm:156-159, 1995.
70. **Creticos, PS**. Immunotherapy. **Clinical Immunology, Principles and Practice.** Editor-in-Chief Robert R. Rich; Section Editor William T. Shearer. Chapter 131: 2002-2018, August 1995.
71. **Creticos, PS**. A review of oral immunotherapy with pollen extracts. **Expressions Monograph 1.** Vol. 1: 11-13, 1995.
72. **Creticos, PS**. Allergic rhinitis. **Current Therapy in Allergy, Immunology and Rheumatology.** Mosby Year-Book, Inc. Editors: Lawrence M. Lichtenstein, Anthony S. Fauci. Fifth edition, Chapter 1: 1 - 8, 1996.
73. **Creticos, PS**. Asthma in adults. **Current Therapy in Allergy, Immunology and Rheumatology.** Mosby Year-Book, Inc. Editors: Lawrence M. Lichtenstein, Anthony S. Fauci. Fifth edition, Chapter 1:36-45, 1996.
74. **Creticos, PS**. Immunotherapy. **Allergy.** W.B. Saunders Publishing Company. Editor Allen P. Kaplan. Second edition, Chapter 45: 726-739, 1997.

75. **Creticos, PS.** Asthma in Adults. **Current Therapy in Adult Medicine.** Mosby Year-Book, Inc. Editors: Jerome P. Kassirer, Harry L. Greene II. Fourth Edition, Chapter 172: 757-765, 1997.
76. **Creticos, PS,** Norman, PS. In vivo provocative testing for IgE-mediated disease. Lockey/Bukantz: **Allergen Immunotherapy,** Marcel Dekker, Inc. Publishers. Chapter 30:499-516, 1998.
77. **Creticos, PS.** Peptide Downregulation of the Immune Response. Academic Press. Editors: Gianni Marone, K. Frank Austen, Stephen T. Holgate, A. Barry Kay, Lawrence M. Lichtenstein. Chapter 30:407-415, 1998.
78. **Creticos, PS.** Pulmicort Turbuhaler® (budesonide inhalation powder). **Clinical Product Monograph.** Published by OCC, Yardley, PA, for Astra USA. 1998.
79. **Creticos, PS,** Freidhoff, LR, Bernstein, DI, et al. Comparison of Triamcinolone acetonide (TAA), Salmeterol xinafoate (SMT), TAA+SMT, and Placebo (PL) in Mild-Moderate Asthmatics. Collegium International Allergology Proceedings. In: **International Archives of Allergy and Immunology.** Feb-Apr;118(2-4):345-6 1999.
80. **Creticos, PS.** Recent Advances in the Management of Allergic Rhinitis and Asthma: A Focus on Monoclonal Antibody Therapy. **ACAAI Newsletter.** March, 2001.
81. **Creticos, PS,** Lichtenstein, LM, Busse WW, et al. Asthma in Adults. **Current Therapy in Allergy, Immunology, and Rheumatology.** Mosby Year-Book Inc. Editors: Lawrence M. Lichtenstein, William M. Busse, Raif S. Geha, Sixth Addition, Chapter 5:31-48. 2003.

#### EDITED BOOKS/MONOGRAPHS:

82. **Creticos, PS.** Editor; Immunotherapy: A Practical Guide of Current Procedures. Editor. Manual developed under the auspices of the American Academy of Allergy and Immunology. 1994.
83. **Creticos, PS.** Editor; Dialogues in Practical Allergy Management Monograph Series. Volume 1: Nos. 1 A Clinical Case in Point: Management of Rhinoconjunctivitis. 2) A Clinical Case in Point: The Patient with Rhinosinusitis. 3) Managing Allergy, Colds, and Flu. 4) The Patient with Asthma. 1993-94.
84. **Creticos, PS.** Co-Editor; Johns Hopkins Asthma and Allergy Website
85. **Creticos, PS.** Series Editor: **Advanced Studies in Medicine Series** – Part I: Advances in Asthma Management. Vol 2, Number 1; January 2002; Part II: Concept to Clinic: Current and Developmental Advances in Asthma Therapy. Vol 2, Number 7; May 2002.
86. **Creticos, PS.** The NHLB Guidelines: Where do we Stand and What is the New Direction from the NAEPP. **Advance Studies in Medicine.** Vol 2, No 14; 499-503, Sept. 2002.
87. **Creticos, PS,** Lichtenstein, LM, Busse WW, et al. Asthma in Adults. **Current Therapy in Allergy, Immunology, and Rheumatology.** Mosby Year-Book Inc. Editors: Lawrence M. Lichtenstein, William M. Busse, Raif S. Geha, Sixth Addition, Chapter 5:31-48. 2003.
88. **Creticos, PS.** Guest Editor: **The Allergy and Immunology Report – An Academic Perspective.** Selected Reports from the 2004 Annual Meeting of the AAAAI. Vol. 1, Number 1, Summer 2004.

#### NON PEER-REVIEWED ARTICLES:

89. **Creticos, PS.** Immunotherapy as an Asthma Trigger. **JAMA: Questions and Answers.** 260 (No. 17): 2571-2572, November, 1988.

90. Chaney, EJ, Bernstein, IL, **Creticos, PS**, Huffman, BL Jr, Knight, A, Selner, JC. IgE-Mediated Allergic Diseases: Diagnosis and Management. **Clinical Courier**, Gardiner-Caldwell SynerMed - Editor. Vol 7, No.4, ISSN 0264-6684:1-8, March 1989.
91. Creticos, PS, Norman, PS. Alerjen Immunoterapisi (JAMA 1987; 258:2874-2880). **Gelism JAMA Haziran**. Cilt 2 Sayi 6:451-458, 1989.
92. **Creticos, PS**. Critical Drug Appraisals: Astemizole. **Drug Therapy**. Vol. 19 (No.10): October 1989.
93. **Creticos, PS**. Immunotherapy – Modulation of inflammation and mediators. Ulrik Gerner Svendsen og Hans-Jorgen Malling, Symposium, Dansk Selskab for Allergologi, Koben-havn; ALK Laboratorierne, Horsholm, Danmark. **Immunotherapy**. 69-71: December 1989.
94. **Creticos, PS**. Rhinitis Otitis, Sinusitis and Eye. **Ann Allergy**. 67:274-277, 1991.
95. **Creticos, PS**. What is the Optimal Dose in Immunotherapy? In: **Perspectives in Immunotherapy**. Proceedings of a Symposium on The Changing Face of Immuootherapy in the 90s. CORE Communications. June 6, 1993.
96. **Creticos, PS**. The Role of Immunotherapy in Asthma. In: **Perspectives in Immunotherapy**. Proceedings of a Symposium on The Changing Face of Immuootherapy in the 90s. CORE Communications. June 6, 1993.
97. **Creticos, PS**. A review of oral immunotherapy. **Proceedings of the University of Genoa Annual Meeting: Highlights in Allergen Specific Immunotherapy**. Vol.1:25-30, 1994.
98. **Creticos, PS**. The Role of IgE in the Pathology of Allergic Disease. **Proceedings of the ACAAI 2000 Annual Meeting, ACAAI Newsletter**.

#### **OTHER MEDIA [FILMS, VIDEOS, CD ROMS, SLIDE SETS, ETC.]**

99. **Creticos, PS**. Advances in Asthma Care. CME accredited slide kit. Editors: AL Sheffer, RA Barbee, WW Busse, SA Murphy, HS Nelson. Publisher: SCP Communications Inc. Supported by an Allen and Hanburys, Division of Glaxo Inc. 1991.
100. **Creticos, PS**. Anaphylactoid Reaction to Sulfites. CME accredited slide/tape set. The Johns Hopkins Medical Grand Rounds. Vol. XVIII, Program 4: 9-14, 1992.
101. **Creticos, PS**. Changing Concepts in Asthma Therapy. CME accredited slide kit. Editors: WC Bailey, B Keown, S Stoloff, K Young. Publisher: Phase Five Communications Inc. Supported by an educational grant by Fisons Pharmaceuticals. 1994.
102. **Creticos, PS**. Allergic Rhinitis: Examining Anti-inflammatory Therapy. CME accredited slide set. Editor: PS Creticos. Publisher: CoMed Communications Inc. Supported by an educational grant from Astra USA. 1996.
103. **Creticos, PS**. Successful Clinical Management of Allergic Rhinitis. Slide set. Editor: PS Creticos. Publisher: Rhone-Poulenc Rorer Pharmaceuticals Inc. 1997.
104. **Creticos, PS** et al. Optimization of Allergen Immunotherapy. CME accredited slide series. Editor: HS Nelson. Publisher: Allergy Laboratories of Copenhagen Educational Department. 1997.

105. **Creticos, PS.** Partners in the Advancement of Allergy Treatment (PAAT). CME accredited slide lecture kit. Publisher: Carlson HealthCare Publications, Inc. Supported by an educational grant from Pfizer Pharmaceuticals. 1998.
106. **Creticos, PS, et al.** Clinical Perspectives on Asthma Management . CD Rom. Supported by an educational grant from GlaxoSmithKline. February 2002.
107. **Creticos, PS, et al.** Allergy One Literature Review Allergist Slide Kit. Publisher: Pharmedica. March 2003.
108. **Creticos, PS, et al.** New Perspectives on Management of Mild Persistent Asthma. CME accredited web-based educational tool. Publisher: Institute for Continuing Health Care Education. Supported by an educational grant from AstraZeneca. December 2003.
109. **Creticos, PS, et al.** Allergy One Literature Review Allergist Slide Kit. Publisher: Pharmedica. March 2004.

#### **ABSTRACTS: [Last Five Years]**

109. **Creticos, PS, Eiden, JJ, Balcer, SL, Van Nest G, Kagey-Sobotka, A, Tuck, SF, Norman, PS, Lichtenstein, LM.** Immunostimulatory Oligonucleotides Conjugated to Amb a 1: Safety, Skin Test Reactivity, and Basophil Histamine Release. **J. Allergy Clin. Immunol.** 105, No. 1, Part 2 S70 (215), 2000.
110. Van Nest, G, Eiden, JJ, Tuck, SF, Kagey-Sobotka, A, **Creticos, PS, Lichtenstein, LM, Spiegelberg, HL, Raz, E.** Conjugation of Immunostimulatory DNA (ISS) to the Major Short Ragweed Allergen, Amb a 1, Enhances Immunogenicity and Reduces Allergenicity. **J. Allergy Clin. Immunol.** 105, No. 1, Part 2 S70 (216), 2000.
111. Columbo, M, Reynolds, C, Beckel, C, Proud, D, Schleimer, RP, Hamilton, RG, Kagey-Sobotka, A, Norman, PS, Heyrman, RM, **Creticos, PS.** Relationships between Symptoms, Mediators, and Cells in the Late-Phase Reaction to Nasal Antigen Challenge. **J. Allergy Clin. Immunol.** 105, No. 1, Part 2 S71 (219), 2000.
112. Marshall, JD, Eiden, JJ, Kagey-Sobotka, A, **Creticos, PS, Lichtenstein, LM, Van Nest, G.** ISS Conjugated to Amb a 1 Allergen Promotes a Th2 to Th1 Switch in PBMC From Ragweed-Allergic Humans. **J. Allergy Clin. Immunol.** 105, No. 1, Part 2, S76 (233), 2000.
113. Heyrman, RM, Columbo, M, Smith, KS, Le, VH, **Creticos, PS.** An Exploratory Multiple Oral Dose Nasal Allergen Challenge Study in Atopic Subjects with Allergic Rhinitis. **J. Allergy Clin. Immunol.** 105, No. 1, Part 2, S203 (608), 2000.
114. **Creticos PS, Balcer SL, Schroeder, RG, Hamilton B, Chung B, Norman PS, Lichtenstein LM, Eiden JJ.** Initial Immunotherapy Trial to Explore the Safety, Tolerability and Immunogenicity of Subcutaneous Injections of an Amb a 1 Immunostimulatory Oligonucleotide Conjugate [AIC] in Ragweed Allergic Adults. **J. Allergy Clin. Immunol.** 107, No. 2, Part 2, S216, 2001.
115. Dieudonné F, Vital Durand D, Eiden J, Tuck G, Van Nest G, Raz E, Hamilton R, **Creticos P.** ISS Linked to Amb a 1 Allergen (AIC) Stimulates IgG Response to Amb a 1 by Ragweed-Allergic Humans. **J. Allergy Clin. Immunol.** 107, No. 2, 933 (3), 2001.
116. **Creticos PS, Eiden JJ, Broide D H, Balcer-Whaley, SL, Schroeder, JT, Khattignavong, A, Li H, Norman P, Hamilton, R.** Immunotherapy with Immunostimulatory Oligonucleotides Linked to Purified Ragweed Amb a 1 Allergen: Effects on Antibody Production, Nasal Allergen Provocation, and Ragweed Seasonal Rhinitis. **J. Allergy Clin. Immunol.** 109, No 4, 743-44 (3) 2002.



- Medical Scientist/Pharm.D. Program  
Program Director Study Period (01/99 – 12/99)  
Sponsor: AstraZeneca 2 Programs
- Pharmaceutical Representative Program  
Program Director Study Period (01/00 – 12/00)  
Sponsor: Glaxo Wellcome, Inc. 3 Programs
- Scientific Specialists Program  
Program Director Study Period (01/00 – 12/00)  
Sponsor: Merck and Co., Inc. 1 Program
- Medical Scientist/PharmD Program  
Program Director Study Period (01/00 – 12/00)  
Sponsor: AstraZeneca 2 Programs  
Grant Award: \$30,000
- Physician Preceptorship Program for Italian Respiratory Specialists  
Program Director Study Period (12/00 – 12/01)  
Sponsor: World WIT
- Pharmaceutical Representative Program  
Program Director Study Period (01/01 – 12/01)  
Sponsor: GlaxoSmithKline 3 Programs
- Pharmaceutical Representative Program  
Program Director Study Period (01/02 – present)  
Sponsor: GlaxoSmithKline 2 Programs
- Medical Scientist/Pharm.D. Program  
Program Director Study Period (07/02-12/02)  
Sponsor: Astra Zeneca 3 Programs (scheduled)
- Pharmaceutical Representative Program  
Program Director Study Period (07/02 – 12/02)  
Sponsor: GlaxoSmithKline 2 Programs (scheduled)
- Pharmaceutical Representative Program  
Program Director Study Period (04/03)  
Sponsor: Altana Pharma 1 Program

#### **OTHER PROFESSIONAL ACCOMPLISHMENTS:**

- Report of the National Institute of Allergy and Infectious Diseases Task Force on Immunology and Allergy US DHHS September 1990 NIH Pub. No. 91-2414 Contributor, Allergic Diseases Section
- Expert Panel of the World Health Organization  
Geneva, Switzerland - January 27-29, 1997  
Development of Position Paper to define international guidelines on allergen immunotherapy [WHO Position Paper: "Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases"]





